Skip to main content
Erschienen in: Wiener klinische Wochenschrift 7-8/2020

14.02.2020 | original article

Presepsin:albumin ratio and C-reactive protein:albumin ratio as novel sepsis-based prognostic scores

A retrospective study

verfasst von: Mustafa Kaplan, MD, Tolga Duzenli, MD, Alpaslan Tanoglu, MD, Basak Cakir Guney, MD, Yesim Onal Tastan, MD, Hatice Selcen Bicer, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2020

Einloggen, um Zugang zu erhalten

Summary

Objective

To investigate the prognostic value of the presepsin:albumin ratio and C‑reactive protein:albumin ratio in patients with sepsis in the intensive care unit (ICU).

Methods

A total of 228 (129 males and 99 females) patients with newly diagnosed sepsis were included in the study. The relationship between the C‑reactive protein:albumin ratio, presepsin:albumin ratio, clinicopathologic parameters, and overall survival were investigated. The associations between C‑reactive protein:albumin ratio and presepsin:albumin ratio were evaluated alongside other inflammation-based prognostic scores such as quick Sepsis Related Organ Failure Assessment (qSOFA).

Results

The presepsin:albumin ratio was significantly higher in non-survivors (p < 0.01). Patients with a high presepsin:albumin ratio had worse overall survival compared with patients with high C‑reactive protein:albumin ratio levels (p < 0.001).

Conclusion

Presepsin and presepsin:albumin ratio are markers of adverse prognosis in patients with sepsis and are superior to C‑reactive protein and C‑reactive protein:albumin ratio for this purpose. Presepsin:albumin ratio may be a novel marker of poor prognosis in patients with sepsis in intensive care units.
Literatur
1.
Zurück zum Zitat Ali TF, Ali AMA, Elnakeeb MM, Bendary NMH. Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis. Clin Chim Acta. 2016;460:93–101.CrossRef Ali TF, Ali AMA, Elnakeeb MM, Bendary NMH. Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis. Clin Chim Acta. 2016;460:93–101.CrossRef
2.
Zurück zum Zitat Protti A, Singer M. Bench-to-bedside review: potential strategies to protect or reverse mitochondrial dysfunction in sepsis-induced organ failure. Crit Care. 2006;10:228.CrossRef Protti A, Singer M. Bench-to-bedside review: potential strategies to protect or reverse mitochondrial dysfunction in sepsis-induced organ failure. Crit Care. 2006;10:228.CrossRef
3.
Zurück zum Zitat Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of presepsin for sepsis in an emergency department. Crit Care. 2013;17:R244.CrossRef Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of presepsin for sepsis in an emergency department. Crit Care. 2013;17:R244.CrossRef
4.
Zurück zum Zitat Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med. 2003;9:517–24.CrossRef Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med. 2003;9:517–24.CrossRef
5.
Zurück zum Zitat Groselj-Grenc M, Ihan A, Pavenik-Arnol M, Kopitar AN, Gmeiner-Stopar T, Derganc M. Neutrophil and monocyte CD64 indexes, lipopolysaccharide-binding protein, procalcitonin and C‑reactive protein in sepsis of critically ill neonates and children. Intensive Care Med. 2009;35(11):1950–8.CrossRef Groselj-Grenc M, Ihan A, Pavenik-Arnol M, Kopitar AN, Gmeiner-Stopar T, Derganc M. Neutrophil and monocyte CD64 indexes, lipopolysaccharide-binding protein, procalcitonin and C‑reactive protein in sepsis of critically ill neonates and children. Intensive Care Med. 2009;35(11):1950–8.CrossRef
6.
Zurück zum Zitat Herzum I, Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem. 2008;15(6):581–7.CrossRef Herzum I, Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem. 2008;15(6):581–7.CrossRef
7.
Zurück zum Zitat Reinhart K, Meisner M, Brinkhorst FM. Markers for sepsis diagnosis: what is useful? Crit Care Clin. 2006;22(3):503–19.CrossRef Reinhart K, Meisner M, Brinkhorst FM. Markers for sepsis diagnosis: what is useful? Crit Care Clin. 2006;22(3):503–19.CrossRef
8.
Zurück zum Zitat Endo S, Aikawa N, Fujishima S, et al. Usefulness of procalcitonin serum level fort he discrimination of severe sepsis: a multicenter prospective study. J Infect Chemother. 2006;14(3):244–9.CrossRef Endo S, Aikawa N, Fujishima S, et al. Usefulness of procalcitonin serum level fort he discrimination of severe sepsis: a multicenter prospective study. J Infect Chemother. 2006;14(3):244–9.CrossRef
9.
Zurück zum Zitat Fairclough E, Cairns E, Hamilton J, Kelly C. Evaluation of a modified early warning system for acute medical admission and comparision with C‑reactive protein/albumin ratio as a predictor of patient outcome. Clin Med. 2009;9:30–3.CrossRef Fairclough E, Cairns E, Hamilton J, Kelly C. Evaluation of a modified early warning system for acute medical admission and comparision with C‑reactive protein/albumin ratio as a predictor of patient outcome. Clin Med. 2009;9:30–3.CrossRef
10.
Zurück zum Zitat Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD 14 is an acute-phase protein. J Immunol. 2004;172(7):4470–9.CrossRef Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD 14 is an acute-phase protein. J Immunol. 2004;172(7):4470–9.CrossRef
11.
Zurück zum Zitat Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:762–74.CrossRef Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:762–74.CrossRef
12.
Zurück zum Zitat Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–54.CrossRef Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–54.CrossRef
13.
Zurück zum Zitat Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States analysis of incidence, outcome and associated costs of care. Crit Care Med. 2001;29:1303–10.CrossRef Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States analysis of incidence, outcome and associated costs of care. Crit Care Med. 2001;29:1303–10.CrossRef
14.
Zurück zum Zitat Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med. 2011;24:12–4.CrossRef Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med. 2011;24:12–4.CrossRef
15.
Zurück zum Zitat Naitoh K, Shirakawa K, Hirose J, et al. The new sepsis marker sCD14-ST (PRESEPSİN): introduction mechanism in the rabbit sepsis mpdels. Crit Care. 2010;14:P19. Naitoh K, Shirakawa K, Hirose J, et al. The new sepsis marker sCD14-ST (PRESEPSİN): introduction mechanism in the rabbit sepsis mpdels. Crit Care. 2010;14:P19.
16.
Zurück zum Zitat Rivers EP, Ahrens T. Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. Crit Care Clin. 2008;24(3):S1–S47.CrossRef Rivers EP, Ahrens T. Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. Crit Care Clin. 2008;24(3):S1–S47.CrossRef
17.
Zurück zum Zitat Endo S, Suzuki Y, Takahashi G, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter pospective study. J Infect Chemother. 2012;18(6):891–7.CrossRef Endo S, Suzuki Y, Takahashi G, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter pospective study. J Infect Chemother. 2012;18(6):891–7.CrossRef
18.
Zurück zum Zitat Glück T, Silver J, Epstein M, Cao P, Farber B, Goyert SM. Parameters influencing membrane CD14 expression and soluble CD14 levels in sepsis. Eur J Med Res. 2001;6(8):351–8.PubMed Glück T, Silver J, Epstein M, Cao P, Farber B, Goyert SM. Parameters influencing membrane CD14 expression and soluble CD14 levels in sepsis. Eur J Med Res. 2001;6(8):351–8.PubMed
19.
Zurück zum Zitat Al-Shaiba R, McMillan DC, Angerson WJ, Leen E, McArdle CS, Horgan P. The relationship between hypoalbuminaemia, tumour volüme and tje systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer. 2004;91(2):205–7.CrossRef Al-Shaiba R, McMillan DC, Angerson WJ, Leen E, McArdle CS, Horgan P. The relationship between hypoalbuminaemia, tumour volüme and tje systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer. 2004;91(2):205–7.CrossRef
20.
Zurück zum Zitat Argiles JM, Busquets S, Lopez-Soriano FJ. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care. 2003;6(4):401–6.PubMed Argiles JM, Busquets S, Lopez-Soriano FJ. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care. 2003;6(4):401–6.PubMed
21.
Zurück zum Zitat Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004;90(9):1704–6.CrossRef Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004;90(9):1704–6.CrossRef
22.
Zurück zum Zitat Kinoshita A, Onoda H, Imai N, et al. The C‑reactive protein/albümin ratio, a novel inflammation-based prognostic score predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22(3):803–10.CrossRef Kinoshita A, Onoda H, Imai N, et al. The C‑reactive protein/albümin ratio, a novel inflammation-based prognostic score predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22(3):803–10.CrossRef
23.
Zurück zum Zitat Liu X, Sun X, Liu J, et al. Preoperative C‑reactive protein/albümin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol. 2015;8(4):339–45.CrossRef Liu X, Sun X, Liu J, et al. Preoperative C‑reactive protein/albümin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol. 2015;8(4):339–45.CrossRef
24.
Zurück zum Zitat Xu XL, Yu HQ, Hu W, Song Q, Mao WM. A novel inflammation-based prognostic score, the C‑reactive protein/albumin ratio predict the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS ONE. 2015;10(9):e138657.CrossRef Xu XL, Yu HQ, Hu W, Song Q, Mao WM. A novel inflammation-based prognostic score, the C‑reactive protein/albumin ratio predict the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS ONE. 2015;10(9):e138657.CrossRef
25.
Zurück zum Zitat Wei XL, Wang FH, Zhang DS, et al. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C‑reactive protein/albumin ratio. BMC Cancer. 2015;15:350.CrossRef Wei XL, Wang FH, Zhang DS, et al. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C‑reactive protein/albumin ratio. BMC Cancer. 2015;15:350.CrossRef
Metadaten
Titel
Presepsin:albumin ratio and C-reactive protein:albumin ratio as novel sepsis-based prognostic scores
A retrospective study
verfasst von
Mustafa Kaplan, MD
Tolga Duzenli, MD
Alpaslan Tanoglu, MD
Basak Cakir Guney, MD
Yesim Onal Tastan, MD
Hatice Selcen Bicer, MD
Publikationsdatum
14.02.2020
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 7-8/2020
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01618-9

Weitere Artikel der Ausgabe 7-8/2020

Wiener klinische Wochenschrift 7-8/2020 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungstipps